Your browser doesn't support javascript.
loading
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera, Jorge E; Wang, Michael; Feng, Lei; Fayad, Luis E; Hagemeister, Frederick; McLaughlin, Peter; Rodriguez, M Alma; Fanale, Michelle; Orlowski, Robert; Kwak, Larry W; Neelapu, Sattva; Oki, Yasuhiro; Pro, Barbara; Younes, Anas; Samaniego, Felipe; Fowler, Nathan; Hartig, Kimberly; Valentinetti, Marisa; Smith, Judy; Ford, Peggy; Naig, Adam; Medeiros, L Jeffrey; Kantarjian, Hagop M; Goy, Andre.
Affiliation
  • Romaguera JE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hagemeister F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McLaughlin P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fanale M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Orlowski R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kwak LW; Lymphoma Center, City of Hope, Duarte, California.
  • Neelapu S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pro B; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Younes A; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fowler N; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hartig K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Valentinetti M; Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, New Jersey.
  • Smith J; Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, New Jersey.
  • Ford P; Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, New Jersey.
  • Naig A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Goy A; Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, New Jersey.
Cancer ; 124(12): 2561-2569, 2018 06 15.
Article in En | MEDLINE | ID: mdl-29723393
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, Mantle-Cell / Chemotherapy-Induced Febrile Neutropenia / Neoplasm Recurrence, Local Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cancer Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, Mantle-Cell / Chemotherapy-Induced Febrile Neutropenia / Neoplasm Recurrence, Local Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cancer Year: 2018 Type: Article